Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel ...

In a deal valued at up to $1 billion, Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's Innovent Biologics, hoping to bring a competitor to Amgen's recently ...

Molecular Partners AG announced positive IND-enabling data for its Radio-DARPin MP0712, targeting DLL3 for small cell lung cancer, at the AACR Annual Meeting 2025. The company is set to enter ...

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting - Zai Lab will highlight potential of ZL-1310 as a promising ...

Dosing underway in Phase 1 clinical trial for ABD-147 (DLL3-targeting radiopharmaceutical ... antibody engineering ROVEr™ platform to design and develop tunable precision radiopharmaceuticals ...

Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering c ...

Delta-like ligand (DLL3) antibody-drug conjugate (ADC) for the treatment of extensive-stage small cell lung cancer (ES-SCLC), will be presented during a poster session at the 2025 American Society ...